EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Stedycon Sted super-resolution fluorescence microscope
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Subscribe To Our Newsletter & Stay Updated
